ArticleBMC biology2025
BiMA-DTI: a bidirectional Mamba-Attention hybrid framework for enhanced drug-target interaction prediction.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPredicting drug-target interactions (DTIs) is essential for accelerating drug discovery, yet traditional experimental methods are time-consuming and costly. Computational approaches, especially those using machine learning and deep learning, offer a more efficient alternative.
resultsThis paper presents the BiMA-DTI framework, which integrates Mamba's State Space Model (SSM) with multi-head attention mechanisms. This combination maximizes Mamba's ability to process long sequences while taking advantage of the attention mechanism's strength in handling short sequences. We designed a hybrid Mamba-Attention Network (MAN) and a Graph Mamba Network (GMN) for processing multimodal inputs, including protein amino acid sequences, Simplified Molecular Input Line Entry System (SMILES) strings, and molecular graphs of drugs, enabling comprehensive feature extraction and fusion. To enhance the complementarity between features extracted from sequences and graphs, BiMA-DTI performs a two-step weighted fusion of sequence features of drugs and proteins with molecular graph features of drugs. Finally, these fused features are concatenated and passed through a fully connected network to predict DTIs.
conclusionsBiMA-DTI demonstrates its potential to discover new drugs, offering a powerful tool for drug discovery. Experimental results show that BiMA-DTI outperforms state-of-the-art competing methods on benchmark datasets. Additionally, ablation experiments validate the rationality of BiMA-DTI's architecture and its generalization ability. Visualization studies provide interpretability of biological mechanisms. Finally, case studies further confirm that BiMA-DTI is a reliable drug-target interaction prediction tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.